Radiopharmaceuticals for Palliation of Bone Pain in Patients with Castration-resistant Prostate Cancer Metastatic to Bone: A Systematic Review

Conclusions Overall, pain response percentages greater than 50–60% were seen with each radionuclide. Haematological toxicity was reported in 26 of the 36 studies and more than half of these trials stated no grade 3/4 leukopenia or thrombocytopenia occurred. Patient summary In this report we reviewed the efficacy of bone-seeking radionuclides for treating bone pain from metastatic prostate cancer. Overall, treatment with bone-seeking radionuclides resulted in pain responses greater than 50–60%. Treatment with a bone-seeking radiopharmaceutical is an effective therapeutic option for patients with castration-resistant prostate cancer suffering from malignant bone pain.
Source: European Urology - Category: Urology & Nephrology Source Type: research